VSTM4: A Potential Drug Target and Biomarker (G196740)
VSTM4: A Potential Drug Target and Biomarker
VSTM4, or VAL642, is a potential drug target and biomarker that is being investigated for its role in the treatment of various diseases, including cancer. VSTM4 is a protein that is expressed in various tissues and organs, including the brain, lungs, and gastrointestinal tract. It is a member of the TGF-β signaling pathway, which is a well-established pathway that plays a role in the development and maintenance of tissues and organs.
One of the unique features of VSTM4 is its ability to interact with multiple cell types and processes. This makes it a potentially promising drug target, as drugs that can interact with this protein have the potential to be highly effective in treating a wide range of diseases. For example, VSTM4 has been shown to be involved in the development and progression of various cancers, including breast, lung, and ovarian cancer.
In addition to its potential as a drug target, VSTM4 has also been identified as a potential biomarker for certain diseases. This is because it is expressed in a variety of tissues and can be used as a protein biomarker for certain conditions, such as cancer. By detecting the level of VSTM4 in tissues or fluids, researchers can monitor the effectiveness of certain treatments and make early assessments of disease progression.
One of the challenges in studying VSTM4 as a drug target is its complex structure and function. While it is known that VSTM4 plays a role in the TGF-β signaling pathway, it is not yet clear exactly how this protein interacts with its downstream targets and how it contributes to the development and progression of diseases.
To address these challenges, researchers are using various techniques to study VSTM4, including biochemical, cellular, and animal models. For example, researchers have used techniques such as mass spectrometry and affinity purification to identify the protein's interacting partners and determine how it functions in different cellular contexts. They have also used cell-based assays to study the effects of drugs on VSTM4 expression and function.
While the study of VSTM4 is still in its early stages, it has the potential to be a valuable drug target and biomarker for a wide range of diseases. If successful, VSTM4 could be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.
In conclusion, VSTM4 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Its complex structure and function make it a challenging target, but its potential impact on the treatment of certain conditions makes it a promising area of research. Further studies are needed to fully understand the role of VSTM4 in the development and progression of diseases.
Protein Name: V-set And Transmembrane Domain Containing 4
Functions: Peptide Lv enhances L-type voltage-gated calcium channel (L-VGCC) currents in retinal photoreceptors
More Common Targets
VSTM5 | VSX1 | VSX2 | VTA1 | VTCN1 | VTI1A | VTI1B | VTN | VTRNA1-1 | VTRNA1-2 | VTRNA1-3 | VTRNA2-1 | VTRNA3-1P | VWA1 | VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45
